by Eclosion Team | Nov 25, 2019 | Uncategorized
Collaboration follows data from ANGEL-MS extension to Phase 2 MS trial Aims to address key unmet need of slowing or stopping disease progression Geneva, Switzerland, November 25, 2019 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO),...
by Eclosion Team | Oct 31, 2019 | Uncategorized
A must-attend and rapidly growing event with experts around the world: 36 speakers from 10 countries In-depth scientific review of the role played by the HERVs in a broad range of diseases including multiple sclerosis, amyotrophic lateral sclerosis and cancer Focus on...
by Eclosion Team | Sep 16, 2019 | Uncategorized
Further evidence adds to already strong set of positive clinical data Data presented at ECTRIMS 2019 Congress in Stockholm, Sweden Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company...
by Eclosion Team | Jul 25, 2019 | Uncategorized
Setanaxib (GKT831) achieved statistical significance (p=0.02) for primary endpoint with the 400mg BID versus placebo, after correction of nonnormal distribution (outliers) in 400mg OD In advanced patients, setanaxib 400mg BID achieved significant reductions in GGT...
by Eclosion Team | Jul 22, 2019 | Uncategorized
World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class The recommended new stem “naxib” recognizes NOX inhibitors as a new therapeutic class The NOX inhibitor therapeutic class has significant potential in...
by Eclosion Team | Jul 17, 2019 | Uncategorized
Study expands potential clinical indications for lead compound Trial fully funded via a grant from the United States National Institutes of Health Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX...
